A genomics pioneer is selling a full DNA analysis for \$1,400. Is it worth it?

Rebecca Robbins @rebeccadrobbins

March 21, 2017 https://www.statnews.com/2017/03/21/craig-venter-sequence-genome/



Mark Wilson/Getty Images

The genomics pioneer who sequenced the human genome carved out a new niche just over a year ago, selling¹ exhaustive \$25,000 medical workups to apparently healthy people. Now Craig Venter's trying to take one small piece of that business to a much wider audience — and to prove it's worthwhile.

An early step in that direction came this month, when Venter's company Human Longevity struck a deal² with a life insurer to boost its \$2,500 whole genome analysis³ product. For a discounted \$1,400, customers and employees of the life insurer, MassMutual, can get every inch of their DNA scoured and then interpreted for what it means for their disease risk. It's a way to "turn risks into opportunities to outsmart the diseases that may lie in your future," Human Longevity's website says of the product.

This is a STAT Plus article and is only available to STAT Plus subscribers. To read the full story, subscribe to STAT Plus or log in to your account. Good news: your first 30 days are on us.

https://www.statnews.com/2015/11/05/geneticist-craig-venter-helped-sequence-the-human-genome-now-he-wants-vours/

^{2.} http://www.humanlongevity.com/human-longevity-inc-and-massmutual-sign-groundbreaking-agreement-to-offer-hliq-whole-genome-sequencing-to-massmutuals-customers-financial-professionals-and-employees/

^{3.} http://www.humanlongevity.com/products/hliq-whole-genome/